ARTICLE AUTHORS
ARTICLE INFO
academic journalism

Detection of Synergistic Antimicrobial Activities of Ceftaroline, Telavancin, Daptomycin, and Vancomycin Against Methicillin-Resistant Staphylococcus aureus Strains in Intensive Care Units

AUTHORS

avatar Laser Şanal 1 , * , avatar Neziha Yılmaz 2 , avatar Hatice Uludag 3 , avatar Reyhan Öztürk 4 , avatar Süha Sen 5 , avatar Salih Cesur 6

1 Microbiology Laboratory, Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey

2 Medical Microbiology Department, Bozok University, Yozgat, Turkey

3 Human Tissue and Cell Laboratory, Yasam Bank, Ankara, Turkey

4 Infectious Diseases Department, Keçiören Training and Research Hospital, Ankara, Turkey

5 Infectious Diseases Department, Beytepe Murat Erdi Eker Hospital, Ankara, Turkey

6 Infectious Diseases Department, Ankara Training and Research Hospital, Ankara, Turkey

How to Cite: Şanal L, Yılmaz N, Uludag H, Öztürk R, Sen S, et al. Detection of Synergistic Antimicrobial Activities of Ceftaroline, Telavancin, Daptomycin, and Vancomycin Against Methicillin-Resistant Staphylococcus aureus Strains in Intensive Care Units. Jundishapur J Microbiol. 2018;11(11):e66445.
doi: 10.5812/jjm.66445.

ARTICLE INFORMATION

Jundishapur Journal of Microbiology: 11 (11); e66445
Published Online: October 17, 2018
Article Type: Research Article
Received: January 18, 2018
Revised: July 19, 2018
Accepted: August 1, 2018
DOI: 10.5812/jjm.66445
https://www.allposters.com.au/-sp/Staphylococcus-Aureus-Bacteria-posters_i9006118_.htm
https://www.allposters.com.au/-sp/Staphylococcus-Aureus-Bacteria-posters_i9006118_.htm
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Background:

Methicillin-resistant Staphylococcus aureus (MRSA) is a leading pathogen of serious infectious diseases in intensive care units. Novel antibiotic combination therapies are needed to treat serious infectious diseases caused by MRSA.

Objectives:

Our objective was to evaluate the minimum inhibitory concentrations (MICs) of ceftaroline (CPT), telavancin (TLV), daptomycin (DPC), and vancomycin (VA) alone and in vitro synergistic activity of CPT-TLV, CPT-DPC, and CPT-VA combinations against MRSA isolates.

Methods:

Fifty MRSA strains isolated from blood (90%) and tracheal aspirate (10%) of patients in intensive care units (ICUs) between 2013 and 2016 were included in the study. The Epsilometer test was used for determining the synergistic activities of antibiotic combinations. We evaluated the synergistic, additive, indifferent, and antagonist effects of MRSA strains by the fractional inhibitory concentration (FIC) index.

Results:

Of the 50 MRSA strains tested, 100% were susceptible to TLV, DPC, and VA. CPT was detected as resistant in 3 (6%) of the isolates. CPT-TLV, CPT-DPC, and CPT-VA combinations were found to have synergistic effects in 14%, 38%, 10% and additive effects in 40%, 32%, and 22% of the isolates, respectively. No antagonism was detected in any of the combinations.

Conclusions:

The combination of CPT with DPC showed the best synergy profile among all antibiotic combinations tested against MRSA isolates obtained from patients in ICUs.

1. Background

Methicillin-resistant Staphylococcus aureus (MRSA) is a leading pathogen of serious infections in intensive care units (1, 2). Methicillin-resistant S. aureus infections are associated with higher morbidity and mortality rates and prolonged hospital stays (3). Although several studies suggest that infections with MRSA have declined in recent years, they are still among the top three clinically important pathogens (4, 5). Methicillin-resistant S. aureus strains are frequently resistant to multiple classes of antimicrobial agents including aminoglycosides, macrolides-lincosamides-streptogramins, and tetracyclines.

Until now, glycopeptides have been considered as the drugs of choice for the treatment of severe MRSA infections (6). However, resistance to vancomycin in MRSA strains has increased recently worldwide (7). Resistance to newer antimicrobial agents such as linezolid, teicoplanin, and daptomycin has also been reported in the studies (8). Alternative therapies including novel combinations are essential to treat MRSA infections. Different antibiotic combinations are frequently used for the treatment of infections caused by MRSA strains (9-14).

2. Objectives

In this study, our objective was to determine the synergistic antimicrobial activities of a newly developed fifth-generation cephalosporin, ceftaroline (CPT), and telavancin (TLV), daptomycin (DPC), and vancomycin (VA) by the Epsilometer test (E-test) against MRSA strains isolated from patients in intensive care units (ICUs).

3. Methods

3.1. Ethics Statement

This study was supported by a Grant from Yüksek İhtisas Training and Research Hospital and approved by its Ethics Committee (Grant No: 328-5).

3.2. Isolates and Antibacterials Assay

We evaluated a total of 50 MRSA strains, isolated from patients in intensive care units between 2013 and 2016. 45 (90%) isolates were obtained from blood and 5 (10%) from tracheal aspirate. The identification of MRSA strains was performed by conventional methods. Antibiotic susceptibility tests and the minimum inhibitory concentration (MIC) values were interpreted in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards (15).

The minimum inhibitory concentration values and the synergy tests were determined by using the E-test method, which is a ‘ready-to-use’ reagent strip with a predefined gradient of antibiotic, according to the manufacturer’s instructions (bioMerieux, France). The minimum inhibitory concentration values were assessed first for CPT, TLV, DPC, and VA alone and then, in combination (CPT-TLV, CPT-DPC, and CPT-VA) for each of the MRSA isolates. First, the bacterial suspensions were prepared to 0.5 MacFarland standard turbidity; then, the suspensions were spread onto 150-mm Mueller-Hinton agar plates. After this procedure, E-test strips (bioMerieux, France) for CPT, TLV, DPC, and VA were placed onto the plates. After the incubation of the plates for 24 h at 37°C, the MIC values were recorded.

We evaluated the synergistic effect of three different antibiotic combinations (CPT-TLV, CPT-DPC, and CPT-VA) by the E test method (bioMerieux, France) against MRSA strains isolated from patients in intensive care units. First, we applied the E test that belonged to antibiotic A to the surface of planted Mueller-Hinton agar. We marked the site at which the E-test strip was placed on the plate and incubated the plates for 1 h at 37°C. Then, we removed the strip and applied the other antibiotic’s strip (antibiotic B) onto the imprint of antibiotic A. At the end, we re-incubated the plates at 37°C for 24 h and recorded the MIC levels of each combination.

3.3. FIC Evaluation

We evaluated the synergistic, additive, indifferent, and antagonist effects of MRSA strains by fractional inhibitory concentration (FIC) index for the combinations of the antibiotics according to the formula given below.

FIC index = FIC A + FIC B

FIC A = The MIC value of antibiotic A in the presence of antibiotic B / The MIC value of single antibiotic A.

FIC B = The MIC value of antibiotic B in the presence of antibiotic A / The MIC value of single antibiotic B.

If the FIC index was ≤ 0.5, we considered the combination as synergistic. We interpreted the combination as additive when the FIC index value was > 0.5 but ≤ 1. We determined the combination as indifferent when the FIC value was > 1 but ≤ 4. We considered the combination as antagonistic when the FIC index value was > 4 (16).

4. Results

Of the 50 MRSA strains tested, 100% were susceptible to TLV, DPC and VA. CPT was detected as resistant in 3 (6%) of the isolates. For CPT, we determined the MIC50 and MIC90 values as 0.5 µg/mL and 1 µg/mL, for TLV as 0.032 µg/mL and 0.064 µg/mL, for DPC as 0.38 µg/mL and 0.75 µg/mL, and for VA as 1 µg/mL and 2 µg/mL, respectively (Table 1). The FIC values and the activities of antibiotic combinations are shown in Table 2. CPT-TLV, CPT-DPC, and CPT-VA combinations were found to have synergistic effects in 14%, 38%, and 10% and additive effects in 40%, 32%, and 22% of the isolates, respectively. No antagonism was detected in any of the combinations (Table 3).

Table 1. Mic Range, MIC50, and MIC90 Values and Susceptibility Rates in Clinically Isolated MRSA Strains in ICUs
AntibioticMIC (µg/mL)Susceptibility Rate (%)
MIC RangeMIC50MIC90SusceptibleResistant
CPT0.19 - 20.501.0946
TLV0.016 - 0.1250.0320.0641000
DPC0.094 - 10.380.751000
VA0.38 - 21.02.01000

Abbreviations: CPT, ceftaroline; DPC, daptomycin; ICUs, intensive care units; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; TLV, telavancin; VA, vancomycin.

Table 2. The FIC Values and the Activities of Antibiotic Combinations Against 50 Clinically Isolated MRSA Strains in ICUs
NoCPT-TLVCPT-DPCCPT-VA
FICActivityFICActivityFICActivity
10.78ADD3.082ID1.166ID
21.085ID0.422S0.751ADD
32.419ID1.776ID2.26ID
40.487S0.508ADD2.186ID
52.824ID0.802ADD1.625ID
61.085ID0.699ADD1.166ID
70.868ADD2.032ID2.5ID
81.128ID2.788ID2.09ID
91.085ID0.416S0.999ADD
101.064ID0.36S1.0ADD
112.064ID0.4S0.568ADD
121.128ID0.845ADD1.166ID
130.974ADD0.428S3.76ID
141.455ID1.361ID1.25ID
150.828ADD0.365S1.13ID
161.125ID0.499S1.666ID
170.968ADD0.824ADD1.38ID
180.823ADD0.888ADD1.58ID
190.756ADD1.064ID2.0ID
201.531ID1.128ID2.25ID
210.42S1.747ID2.157ID
220.423S0.26S0.594ADD
230.965ADD0.747ADD1.494ID
241.166ID1.172ID1.166ID
251.256ID0.456S1.76ID
260.778ADD0.418S1.32ID
271.047ID0.375S0.5S
280.536ADD0.427S0.565ADD
290.574ADD0.755ADD1.125ID
300.595ADD0.919ADD1.333ID
310.484S0.458S0.5S
320.737ADD0.661ADD0.91ADD
330.803ADD0.494S1.666ID
340.742ADD0.633ADD0.916ADD
350.536ADD0.44S1.13ID
360.382S0.419S1.666ID
370.688ADD0.622ADD1.126ID
380.803ADD0.413S1.661ID
390.808ADD1.5ID1.128ID
400.444S0.381S0.5S
411.247ID0.874ADD1.0ID
420.418S0.75ADD0.458S
431.724ID2.256ID1.25ID
441.054ID0.496S0.874ADD
452.419ID1.0ADD1.51ID
460.782ADD2.247ID0.254S
471.047ID2.785ID0.94ADD
481.062ID0.835ADD0.833ADD
491.724ID1.256ID2.835ID
501.188ID2.02ID2.26ID

Abbreviations: ADD, additive; ANT, antagonistic; CPT, ceftaroline; DPC, daptomycin; FIC, fractional inhibitory concentration; ICUs, intensive care units; ID, indifferent; MRSA, methicillin resistant Staphylococcus aureus; S, synergistic; TLV, telavancin; VA, vancomycin.

Table 3. Synergy Test Results of CPT-TLV, CPT-DPC, and CPT-VA Combinations Against MRSA Isolatesa
Combination Synergistic EffectAdditive EffectIndifferent EffectAntagonistic Effect
CPT-TLV7 (14)20 (40)23 (46)0 (0)
CPT-DPC19 (38)16 (32)15 (30)0 (0)
CPT-VA5 (10)11 (22)34 (68)0 (0)

Abbreviations: CPT, ceftaroline; DPC, daptomycin; MRSA, methicillin resistant Staphylococcus aureus; TLV, telavancin; VA, vancomycin.

aData are presented as No. (%) of bacterial strains.

5. Discussion

Staphylococcus aureus is a serious human pathogen worldwide that causes a broad range of clinical infections (17). MRSA is a common infectious agent that causes both nosocomial and community-acquıred infections and it keeps high morbidity and mortality rates (18). The combination of antibiotics acting by different mechanisms is recommended for the treatment of MRSA infections in order to ensure a synergistic action, reduce the occurrence of side-effects, and decrease the risk of resistance. These different antibiotic combinations offer a potential option in the management of the infections caused by MRSA (9-14). In our study, the E test method was used to evaluate the synergistic effects of the antibiotics against MRSA strains isolated from patients in intensive care units. Time-kill and checkerboard tests can be employed to assess the synergy of antibiotic combinations. These methods are costly in time and materials. The E test method is simple to use, time-efficient, and inexpensive. It can be used in routine clinical practice (19).

The glycopeptide VA was proposed as the best alternative for the treatment of MRSA strains. However, a number of studies established a relationship between elevated VA MICs and treatment failures in patients infected with MRSA strains (20-23). According to Thati et al. (20), the MIC for 335 out of 358 isolates (93.57%) for VA was ≤ 2 µg/mL and the MIC values indicated that 1.9% of the MRSA isolates were resistant to vancomycin. Chadha et al. investigated the susceptibility to VA in 163 clinical isolates of MRSA by using E-test methodology and determined the susceptibility rate as 99%. For VA, 56% of the isolates had MICs of ≤ 1.0 µg/mL and 43% had MICs of ≥ 1.5 µg/mL (24). Rybak et al. investigated the susceptibility to VA in 50 MRSA isolates. MIC50 and MIC90 values were 0.50 µg/mL and 1 µg/mL, respectively, and the MIC range was 0.25 - 2.0µg/mL for VA (25). Sader et al. investigated the susceptibility to VA in 9875 MRSA isolates. The MIC50/90 values were 1/1 µg/mL for VA. The susceptibility rate to VA was > 99.9% (26). In the present study, we determined all the strains as susceptible to vancomycin. MIC50 and MIC90 values for VA were 1 µg/mL and 2 µg/mL, respectively. The MIC range was 0.38 - 2.0 µg/mL.

Telavancin, which is derived from vancomycin, has a potent bactericidal activity against Gram-positive bacteria, including MSSA, MRSA, VISA, and MDR (multi-drug resistant) streptococci and enterococci (27, 28). Smith et al. determined the MICs for TLV by broth microdilution method in 70 DNS S. aureus and 100 VISA strains. The MIC50 and MIC90 values were 0.06 - 0.125 for both DNS S. aureus and VISA strains (29). Mendes et al. determined the MIC50/90 values as 0.03/0.06 µg/mL for TLV against 4651 MRSA strains (27). In the present study, we determined the MIC50 and MIC90 values for TLV as 0.032 µg/mL and 0.064 µg/mL, respectively. The MIC range was 0.016 - 0.125 µg/mL.

Ceftaroline is a novel fifth-generation cephalosporin that demonstrates in vitro activity against Gram-positive and Gram-negative pathogens. It also demonstrates a potent activity against resistant strains of S. aureus (30). Chadha et al. investigated the susceptibility to CPT in 163 clinical isolates of MRSA by using E-test methodology and determined the susceptibility rate as 99%. MIC50 value was 0.5 µg/mL and MIC90 value was 1 µg/mL for CPT (24). Sader et al. determined the MIC50/90 values as 0.5/1 µg/mL for CPT against 9875 MRSA strains. The susceptibility rate was 97.2% for CPT (26). Bilmen et al. investigated 60 MRSA isolates. The MIC50/90 values were found to be 0.5/1 µg/mL and the MIC range was 0.125 - 2 µg/mL for CPT (31). Gaikwad et al. determined MIC50/90 values as 0.38/0.75 µg/mL and the MIC range as 0.25 - 4 µg/mL against 30 MRSA strains for CPT (32). In the present study, 3 (6%) of the strains were resistant to CPT. The MIC50/90 values were 0.5/1 µg/mL and the MIC range was 0.19 - 2 µg/mL for CPT.

Daptomycin is a semisynthetic lipopeptide that shows bactericidal activity against drug-resistant Gram-positive bacteria including MRSA. Daptomycin is being increasingly used in the treatment of complex MRSA infections (33). Chadha et al. investigated the susceptibility to DPC in 163 clinical isolates of MRSA by using E-test methodology and determined the susceptibility rate as 99%. For DPC, 99% of the isolates had MICs of ≤ 1.0 µg/mL (24). Rybak et al. investigated the susceptibility to DPC in 50 MRSA isolates. The MIC50 and MIC90 values were 0.13 µg/mL and the MIC range was 0.06 - 0.5 µg/mL for DPC (25). Smith et al. determined the MIC50/90 values as 2/4 µg/mL in 70 DNS S. aureus strains and 1/1 µg/mL in 100 VISA strains (29). Mendes et al. determined the MIC50/90 values as 0.25/0.5µg/mL in 4651 MRSA strains (27). Sader et al. determined the MIC50/90 values as 0.25/0.5 µg/mL in 9875 MRSA strains for DPC (26). In the present study, all the strains were susceptible to DPC. The MIC50 and MIC90 values were 0.38 µg/mL and 0.75 µg/mL, respectively, and the MIC range was 0.094 - 1.0 µg/mL for DPC.

Recent studies have suggested an enhanced activity for DPC against MRSA when combined with CPT (12, 34, 35). Similarly, in the present study, the combination of CPT with DPC showed the best synergy profile (38% synergistic and 32% additive) among all antibiotic combinations tested against MRSA isolates obtained from patients in ICUs. There are several limitations in this study that should be noted. There is no gold standard for synergy testing. Different methodologies can be used to assess synergy between antibiotics like checkerboard assay or time-kill analysis. These methods are difficult, expensive, and time-consuming for routine antimicrobial synergy testing. Therefore, we preferred the E test method. E-test is much easier to perform, less labor intensive, and less time consuming and may be suitable for routine laboratory testing. These features of the E-test method encouraged us to determine synergistic effects by E-test. Further studies to compare the E-test technique with the checkerboard or time-kill methodologies for the determination of synergy between these antibiotics will strengthen the results of the study. In addition, in vitro studies have limited value in the prediction of in vivo synergy. The ability of in vitro combination testing to determine clinical synergy is unknown. The clinical benefits of these antibiotic combinations in vivo must be done before being used therapeutically.

5.1. Conclusions

In the present study, the antimicrobial activities of CPT, which is a newly developed fifth-generation cephalosporin, and TLV, DPC, and VA combinations, have been studied with the aim of developing new therapeutic options for infections caused by MRSA strains isolated from patients in ICUs. The combination of CPT with DPC showed the best synergy profile (38% synergistic and 32% additive) among all antibiotic combinations. All these data will help clinicians to determine the appropriate antibiotic combinations against infections caused by MRSA strains.

Acknowledgements

References

  • 1.

    Thompson DS. Methicillin-resistant Staphylococcus aureus in a general intensive care unit. J R Soc Med. 2004;97(11):521-6. doi: 10.1258/jrsm.97.11.521. [PubMed: 15520145]. [PubMed Central: PMC1079644].

  • 2.

    Haddadin AS, Fappiano SA, Lipsett PA. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J. 2002;78(921):385-92. [PubMed: 12151652]. [PubMed Central: PMC1742438].

  • 3.

    Hanberger H, Walther S, Leone M, Barie PS, Rello J, Lipman J, et al. Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: Results from the EPIC II study. Int J Antimicrob Agents. 2011;38(4):331-5. doi: 10.1016/j.ijantimicag.2011.05.013. [PubMed: 21798720].

  • 4.

    Landrum ML, Neumann C, Cook C, Chukwuma U, Ellis MW, Hospenthal DR, et al. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA. 2012;308(1):50-9. doi: 10.1001/jama.2012.7139. [PubMed: 22760291].

  • 5.

    Erdem H, Dizbay M, Karabey S, Kaya S, Demirdal T, Koksal I, et al. Withdrawal of Staphylococcus aureus from intensive care units in Turkey. Am J Infect Control. 2013;41(11):1053-8. doi: 10.1016/j.ajic.2013.01.041. [PubMed: 23663858].

  • 6.

    Denis O, Deplano A, Nonhoff C, Hallin M, De Ryck R, Vanhoof R, et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother. 2006;50(8):2680-5. doi: 10.1128/AAC.00272-06. [PubMed: 16870758]. [PubMed Central: PMC1538679].

  • 7.

    Hasan R, Acharjee M, Noor R. Prevalence of vancomycin resistant Staphylococcus aureus (VRSA) in methicillin resistant S. aureus (MRSA) strains isolated from burn wound infections. Ci Ji Yi Xue Za Zhi. 2016;28(2):49-53. doi: 10.1016/j.tcmj.2016.03.002. [PubMed: 28757721]. [PubMed Central: PMC5442891].

  • 8.

    Kaur DC, Chate SS. Study of antibiotic resistance pattern in methicillin resistant Staphylococcus aureus with special reference to newer antibiotic. J Glob Infect Dis. 2015;7(2):78-84. doi: 10.4103/0974-777X.157245. [PubMed: 26069428]. [PubMed Central: PMC4448330].

  • 9.

    Ribes S, Pachon-Ibanez ME, Dominguez MA, Fernandez R, Tubau F, Ariza J, et al. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides. Eur J Clin Microbiol Infect Dis. 2010;29(11):1361-7. doi: 10.1007/s10096-010-1007-y. [PubMed: 20680368]. [PubMed Central: PMC3128719].

  • 10.

    Dhand A, Sakoulas G. Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Clin Ther. 2014;36(10):1303-16. doi: 10.1016/j.clinthera.2014.09.005. [PubMed: 25444563].

  • 11.

    Sueke H, Kaye SB, Neal T, Hall A, Tuft S, Parry CM. An in vitro investigation of synergy or antagonism between antimicrobial combinations against isolates from bacterial keratitis. Invest Ophthalmol Vis Sci. 2010;51(8):4151-5. doi: 10.1167/iovs.09-4839. [PubMed: 20335613].

  • 12.

    Barber KE, Werth BJ, Rybak MJ. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. J Antimicrob Chemother. 2015;70(2):505-9. doi: 10.1093/jac/dku378. [PubMed: 25246437]. [PubMed Central: PMC4291233].

  • 13.

    Werth BJ, Barber KE, Ireland CE, Rybak MJ. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother. 2014;58(6):3177-81. doi: 10.1128/AAC.00088-14. [PubMed: 24663016]. [PubMed Central: PMC4068431].

  • 14.

    Silva LV, Araujo MT, Santos KR, Nunes AP. Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp strains. Mem Inst Oswaldo Cruz. 2011;106(1):44-50. [PubMed: 21340354].

  • 15.

    The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0. 2016. Available from: http://www.eucast.org.

  • 16.

    Mitsugui CS, Tognim MC, Cardoso CL, Carrara-Marroni FE, Botelho Garcia L. In vitro activity of polymyxins in combination with beta-lactams against clinical strains of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2011;38(5):447-50. doi: 10.1016/j.ijantimicag.2011.06.012. [PubMed: 21872449].

  • 17.

    Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG, Jr. Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603-61. doi: 10.1128/CMR.00134-14. [PubMed: 26016486]. [PubMed Central: PMC4451395].

  • 18.

    Raygada JL, Levine DP. Methicillin-resistant Staphylococcus aureus: A growing risk in the hospital and in the community. Am Health Drug Benefits. 2009;2(2):86-95. [PubMed: 25126276]. [PubMed Central: PMC4115307].

  • 19.

    White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: Time-kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996;40(8):1914-8. [PubMed: 8843303]. [PubMed Central: PMC163439].

  • 20.

    Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin resistant Staphylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad. Indian J Med Res. 2011;134(5):704-8. doi: 10.4103/0971-5916.91001. [PubMed: 22199111]. [PubMed Central: PMC3249970].

  • 21.

    Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med. 2006;166(19):2138-44. doi: 10.1001/archinte.166.19.2138. [PubMed: 17060545].

  • 22.

    van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755-71. doi: 10.1093/cid/cir935. [PubMed: 22302374].

  • 23.

    Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: A global analysis 2004-2009. Int J Antimicrob Agents. 2011;37(3):219-24. doi: 10.1016/j.ijantimicag.2010.10.029. [PubMed: 21239146].

  • 24.

    Chadha P, Mariano N, LaBombardi V, Segal-Maurer S, Urban C. In vitro activities of mupirocin, tigecycline, ceftaroline, vancomycin, linezolid and daptomycin in clinical isolates of methicillin-resistant Staphylococcus aureus by E-test methodology. Open J Med Microbiol. 2015;5(1):12-6. doi: 10.4236/ojmm.2015.51002.

  • 25.

    Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob Agents Chemother. 2000;44(4):1062-6. [PubMed: 10722513]. [PubMed Central: PMC89814].

  • 26.

    Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrob Agents Chemother. 2013;57(7):3178-81. doi: 10.1128/AAC.00484-13. [PubMed: 23629712]. [PubMed Central: PMC3697312].

  • 27.

    Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States. Antimicrob Agents Chemother. 2015;59(3):1811-4. doi: 10.1128/AAC.04616-14. [PubMed: 25561335]. [PubMed Central: PMC4325802].

  • 28.

    Leonard SN, Vidaillac C, Rybak MJ. Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2009;53(7):2928-33. doi: 10.1128/AAC.01544-08. [PubMed: 19414568]. [PubMed Central: PMC2704675].

  • 29.

    Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models. Antimicrob Agents Chemother. 2015;59(9):5529-34. doi: 10.1128/AAC.00773-15. [PubMed: 26124162]. [PubMed Central: PMC4538535].

  • 30.

    Maselli DJ, Fernandez JF, Whong CY, Echevarria K, Nambiar AM, Anzueto A, et al. Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia. Infect Drug Resist. 2012;5:43-51. doi: 10.2147/IDR.S17433. [PubMed: 22355258]. [PubMed Central: PMC3278208].

  • 31.

    Bilmen FB, Turhanoglu, M . Antimicrobial activity of ceftaroline and ceftobiprole tested against MRSA isolates from Turkey, in 2016. IOSR J Pharm Biol Sci (IOSR-JPBS). 2016;11(1):52-6. doi: 10.9790/3008-11145256.

  • 32.

    Gaikwad V, Gohel T, Panickar S, Chincholkar V, Mangalkar S. In vitro activity of ceftaroline: A novel antibiotic against methicillin-resistant Staphylococcus aureus. Indian J Pathol Microbiol. 2016;59(4):496-8. doi: 10.4103/0377-4929.191798. [PubMed: 27721280].

  • 33.

    Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40(7):1058-60. doi: 10.1086/428616. [PubMed: 15825002].

  • 34.

    Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014;36(10):1317-33. doi: 10.1016/j.clinthera.2014.05.061. [PubMed: 25017183].

  • 35.

    Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, et al. beta-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother. 2012;56(12):6192-200. doi: 10.1128/AAC.01525-12. [PubMed: 22985884]. [PubMed Central: PMC3497165].

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: